Pharmacist-designed and -implemented pharmaceutical care plan for antipsychotic-induced movement disorders

Pharmacotherapy

Volumn 20, Issue 5, 2000, Pages 583-588

  Stoner, Steven C ^a,b,c   Worrel, Jodi A ^d   Jones, Michael T ^a,c   Farrar, Cynthia A ^c   Ramlatchman, Leonard V ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c St Cloud Vet Aff Medical Center ^*  (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ANTICHOLINERGIC EFFECT; ARTICLE; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE PLANNING; MOTOR DYSFUNCTION; PHARMACIST; PSYCHOSIS; RATING SCALE; TREATMENT OUTCOME;

EID: 0034073908     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.6.583.35159     Document Type: Article

References (25)

1. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999;60(suppl 5):43-7.
2. Lohr JB, Caliguiri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57(4):167-73.
3. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58(5):205-11.
4. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicentre risperidone study. J Clin Psychopharmacol 1995;15(suppl 1):36S-44
5. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154(9):1248-54.
6. Gelenberg AJ. Treating extrapyramidal reactions: some current issues. J Clin Psychiatry 1987;48(suppl 9):24-7.
7. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 1994;14(5): 543-60.
8. Casey DE. Neuroleptic induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993;16(3):589-610.
9. Lane RL, Hunter KA. Drug induced movement disorders. U.S. Pharmacist 1996;October:HS31-42.
10. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63.
11. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-50.
12. Van Putten T, May PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978;35:1101-7.
13. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;75:1054-60.
14. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998;59(suppl 12):23-7.
15. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-22.
16. Jeste DV, Lohr JB, Clark K, Wyatl RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988;8(suppl):38S-48
17. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999; 156(8): 1279-81.
18. Simpson GN, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(suppl 44):11-19.
19. Simpson GN, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171-9.
20. Guy W, ed. ECDEU assessment manual for psychopharmacology, rev. ed. Washington. DC: U.S. Department of Health, Education, and Welfare, 1976.
21. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the abnormal involuntary movements scale. J Nerv Ment Dis 1985;173: 353-7.
22. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Commun Psychiatry 1988;39:1172-7.
23. Sprague RL, Kalachnik JE. Reliability, validity, and a total score cut-off for the dyskinesia identification system (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacol Bull 1991;21:51-8.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia: its validity and significance. Psychiatr Dev 1987;5:79-103.
25. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.